These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. Zhang T; Dhawan MS; Healy P; George DJ; Harrison MR; Oldan J; Chin B; Armstrong AJ Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161 [TBL] [Abstract][Full Text] [Related]
5. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide. Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346 [TBL] [Abstract][Full Text] [Related]
6. Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Caram MEV; Kumbier K; Tsao PA; Burns J; Sparks JB; Stensland KD; Reichert ZR; Alumkal JJ; Hollenbeck BK; Shahinian V; Tsodikov A; Skolarus TA Cancer Med; 2024 Jun; 13(12):e7334. PubMed ID: 39143030 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Azad AA; Eigl BJ; Murray RN; Kollmannsberger C; Chi KN Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038 [TBL] [Abstract][Full Text] [Related]
8. No significant impact of response to prior androgen receptor-axis-targeted agents on the efficacy of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer. Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A Int J Clin Oncol; 2018 Jun; 23(3):576-583. PubMed ID: 29275450 [TBL] [Abstract][Full Text] [Related]
9. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061 [TBL] [Abstract][Full Text] [Related]
10. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193 [TBL] [Abstract][Full Text] [Related]
11. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China. Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815 [TBL] [Abstract][Full Text] [Related]
12. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents. Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719 [TBL] [Abstract][Full Text] [Related]
13. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC). Vestris PG; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L Prostate; 2022 Feb; 82(2):269-275. PubMed ID: 34822183 [TBL] [Abstract][Full Text] [Related]
14. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients. Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan. Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813 [TBL] [Abstract][Full Text] [Related]
16. Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. Buttigliero C; Tucci M; Sonetto C; Vignani F; Di Stefano RF; Pisano C; Turco F; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M Minerva Urol Nefrol; 2020 Dec; 72(6):737-745. PubMed ID: 32284527 [TBL] [Abstract][Full Text] [Related]
17. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845 [TBL] [Abstract][Full Text] [Related]
18. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience. Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919 [TBL] [Abstract][Full Text] [Related]
19. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices. Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646 [TBL] [Abstract][Full Text] [Related]
20. The Effect of Treatment Sequence on Overall Survival for Men With Metastatic Castration-resistant Prostate Cancer: A Multicenter Retrospective Study. Okita K; Hatakeyama S; Narita S; Takahashi M; Sakurai T; Kawamura S; Hoshi S; Ishida M; Kawaguchi T; Ishidoya S; Shimoda J; Sato H; Mitsuzuka K; Ito A; Tsuchiya N; Arai Y; Habuchi T; Ohyama C Clin Genitourin Cancer; 2020 Apr; 18(2):e103-e111. PubMed ID: 31810867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]